Core 1: Biospecimen/Pathology

摘要-生物科学/病理学核心(核心1) Duke癌症健康差异P20孢子(DCHD)的生物谱/病理学核心利用和 被安置在杜克癌症研究所的生物仓库和精密病理中心(BRPC)。BRPC是一种 杜克癌症研究所的共享资源，部分由杜克癌症中心支持赠款提供支持 (5P30-CA014236-45)。这家由NCI资助的共享服务中心获得了患者对血液和 组织样本捐赠和获取、加工和储存液体和组织生物样本，支持 杜克大学患者来源的异种移植和原代肿瘤细胞培养服务的“活生物库”，以及 实施生物信息学和临床策略，以进行精确的样本和模型注释。对于DCHD来说， CORE将高效地提供高质量的组织、血液和液体生物检疫和加工服务，以 请求调查人员，并随着研究人员需求的发展继续调整做法(目标1)；支持当前 和未来的DCHD P20项目，通过扩展组织采购、加工、 和样本管理(目标2)；并教育地方、区域和国家社区认识到 生物医学研究中可用的生物样品和数据的可用性 代表不足的少数群体(目标3)。公爵BRPC最近被授予NCI UM1加入 合作人体组织网络(CHTN)(www.chtn.org)；这个生物信息库网络将支持 来自全国各地的更深层次的世代。对于建议的项目，我们将提供适当的 来自多个种族/民族的肺癌标本和相关数据(项目1)，以及胃活检 黑人患者幽门螺杆菌阳性(项目2)。将对未来试点项目的需求进行评估 可行性；鉴于BRPC现有的图书馆，最近对代表不足的少数群体包容的关注，以及CHTN 参与，广泛的癌症差异研究应该是可能的。此核心完全集成到 DCHD是其成功的关键。

ABSTRACT – Biospecimen/Pathology Core (Core 1) The Biospecimen/Pathology Core of the Duke Cancer Health Disparities P20 SPORE (DCHD) leverages and is housed in the Duke Cancer Institute’s BioRepository & Precision Pathology Center (BRPC). The BRPC is a Shared Resource of the Duke Cancer Institute and supported in part by the Duke Cancer Center Support Grant (5P30-CA014236-45). This NCI-funded shared service center obtains broad consent from patients for blood and tissue sample donation and procures, processes and banks both liquid and tissue biospecimens, supports Duke’s “living biobank” with the Duke Patient-Derived Xenograft and Primary Tumor Cell Culture Services, and implements bioinformatic and clinical strategies for precise sample and model annotation. For the DCHD, the Core will efficiently provide high-quality tissue, blood and fluid-based biospecimens and processing services to requesting investigators, and continue to adjust practices as researcher needs evolve (Aim 1); support current and future DCHD P20 projects through expansion of existing best practices in tissue procurement, processing, and sample management (Aim 2); and educate the local, regional and national community on the importance of available biospecimens in biomedical research to enhance availability of specimens and data from underrepresented minorities (Aim 3). The Duke BRPC has recently been awarded an NCI UM1 to join the Cooperative Human Tissue Network (CHTN)(www.chtn.org); this network of biorepositories will support deeper cohort generation from across the country. For the proposed Projects, we will provide appropriate lung cancer specimens and associated data from multiple races/ethnicities (Project 1), and stomach biopsies positive for H. pylori from Black patients (Project 2). The needs of future Pilot Projects will be assessed for feasibility; given the BRPC’s existing library, a recent focus on underrepresented minority inclusion, and CHTN participation, a wide range of cancer disparities research should be possible. This Core is fully integrated into the DCHD and is critical for its success.